Q4 2018 EPS Estimates for Spark Therapeutics Inc Increased by William Blair (ONCE)

Spark Therapeutics Inc (NASDAQ:ONCE) – Equities research analysts at William Blair boosted their Q4 2018 earnings per share estimates for Spark Therapeutics in a research report issued on Tuesday, November 6th. William Blair analyst R. Prasad now anticipates that the biotechnology company will post earnings of ($0.69) per share for the quarter, up from their prior forecast of ($1.06). William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Spark Therapeutics’ Q1 2019 earnings at ($1.00) EPS, Q2 2019 earnings at ($1.04) EPS, Q3 2019 earnings at ($0.41) EPS, Q4 2019 earnings at ($0.73) EPS, FY2019 earnings at ($3.17) EPS, FY2020 earnings at ($3.83) EPS, FY2021 earnings at ($4.85) EPS and FY2022 earnings at ($4.46) EPS.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The business had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $27.44 million. During the same period last year, the business earned ($1.90) earnings per share. The company’s revenue for the quarter was up 463.2% compared to the same quarter last year.

Several other research firms have also commented on ONCE. Royal Bank of Canada lowered shares of Spark Therapeutics from an “outperform” rating to a “sector perform” rating and set a $100.00 price target on the stock. in a research report on Thursday, July 19th. Cantor Fitzgerald set a $103.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, July 16th. ValuEngine lowered shares of Spark Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 24th. Raymond James set a $82.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 8th. Finally, SunTrust Banks reduced their price target on shares of Spark Therapeutics to $61.00 and set a “buy” rating on the stock in a research report on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $68.52.

ONCE stock opened at $42.76 on Friday. The company has a market cap of $1.71 billion, a PE ratio of -5.60 and a beta of 2.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.14 and a current ratio of 10.71. Spark Therapeutics has a one year low of $39.01 and a one year high of $96.59.

A number of institutional investors have recently bought and sold shares of ONCE. Partner Fund Management L.P. increased its holdings in Spark Therapeutics by 37.5% in the 2nd quarter. Partner Fund Management L.P. now owns 876,779 shares of the biotechnology company’s stock valued at $72,562,000 after purchasing an additional 239,143 shares during the last quarter. BlackRock Inc. increased its holdings in Spark Therapeutics by 8.7% in the 2nd quarter. BlackRock Inc. now owns 2,869,232 shares of the biotechnology company’s stock valued at $237,459,000 after purchasing an additional 229,786 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Spark Therapeutics by 38.3% in the 3rd quarter. Alliancebernstein L.P. now owns 531,184 shares of the biotechnology company’s stock valued at $28,976,000 after purchasing an additional 147,158 shares during the last quarter. FMR LLC increased its holdings in Spark Therapeutics by 2.6% in the 2nd quarter. FMR LLC now owns 5,536,564 shares of the biotechnology company’s stock valued at $458,206,000 after purchasing an additional 142,428 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in Spark Therapeutics by 34.2% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 476,121 shares of the biotechnology company’s stock valued at $25,972,000 after purchasing an additional 121,438 shares during the last quarter.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Recommended Story: Initial Public Offering (IPO)

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply